Asset Details
Do you wish to reserve the book?
CAR T therapy beyond cancer: the evolution of a living drug
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CAR T therapy beyond cancer: the evolution of a living drug
Do you wish to request the book?
CAR T therapy beyond cancer: the evolution of a living drug
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CAR T therapy beyond cancer: the evolution of a living drug
2023
Overview
Engineering a patient’s own T cells to selectively target and eliminate tumour cells has cured patients with untreatable haematologic cancers. These results have energized the field to apply chimaeric antigen receptor (CAR) T therapy throughout oncology. However, evidence from clinical and preclinical studies underscores the potential of CAR T therapy beyond oncology in treating autoimmunity, chronic infections, cardiac fibrosis, senescence-associated disease and other conditions. Concurrently, the deployment of new technologies and platforms provides further opportunity for the application of CAR T therapy to noncancerous pathologies. Here we review the rationale behind CAR T therapy, current challenges faced in oncology, a synopsis of preliminary reports in noncancerous diseases, and a discussion of relevant emerging technologies. We examine potential applications for this therapy in a wide range of contexts. Last, we highlight concerns regarding specificity and safety and outline the path forward for CAR T therapy beyond cancer.
The rationale behind chimaeric antigen receptor T cell therapy is reviewed, and current challenges in oncology, preliminary reports in noncancerous diseases and relevant emerging technologies are discussed.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antigens
/ Autoimmune Diseases - therapy
/ Cancer
/ Cells
/ Disease
/ Fibrosis
/ Hematologic Neoplasms - immunology
/ Hematologic Neoplasms - therapy
/ HIV
/ Human immunodeficiency virus
/ Humanities and Social Sciences
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Immunotherapy, Adoptive - methods
/ Immunotherapy, Adoptive - trends
/ Oncology
/ Patients
/ Receptors, Chimeric Antigen - therapeutic use
/ Science
/ Success
/ Therapy
/ Tumors
